CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
Rhea-AI Summary
CNS Pharmaceuticals (NASDAQ:CNSP) announced three abstracts accepted for poster presentation at the Society for Neuro-Oncology (SNO) 30th Annual Meeting, Nov 19-23, 2025, in Honolulu, HI.
All three posters will be presented by Sandra Silberman, MD, PhD, CNS chief medical officer: preliminary activity of berubicin against pediatric diffuse midline glioma (DMG) on Nov 21, 2025; planned Phase 2 evaluation of TPI 287 plus bevacizumab and other CNS indications on Nov 22, 2025; and primary randomized trial results comparing berubicin vs lomustine in glioblastoma after prior therapy on Nov 22, 2025.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, CNSP declined 1.22%, reflecting a mild negative market reaction. Argus tracked a peak move of +24.8% during that session. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $47K from the company's valuation, bringing the market cap to $4M at that time. Trading volume was very high at 3.4x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that three abstracts have been selected for poster presentation at the 2025 SNO Annual Meeting being held November 19-23, 2025 in Honolulu, HI.
Details of the poster presentations are as follows:
Title: Activity of Berubicin against Pediatric Diffuse Midline Glioma (DMG) cells: Preliminary data and future possibilities
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: EXTH-133
Date and Time: Friday, November 21, 2025 at 11:45 am - 1:05 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
Title: TPI 287, which in combination with Bevacizumab (BEV) has shown activity in patients with glioblastoma (GBM) after prior therapy, will be evaluated in a Phase 2 trial as well as in other CNS diseases
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: CTNI-70
Date and Time: Saturday, November 22, 2025 at 11:45 am - 1:05 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
Title: Primary results of the randomized clinical trial of Berubicin vs Lomustine in patients with glioblastoma after failure of primary therapy: Data analysis and future possibilities
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: CTNI-74
Date and Time: Saturday, November 22, 2025 at 11:30 am - 12:45 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
For more information about the event, please visit the meeting website.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When will CNS Pharmaceuticals (CNSP) present berubicin DMG data at SNO 2025?
What CNSP poster covers TPI 287 plus bevacizumab and when is it presented?
When will CNSP present the randomized trial results of berubicin vs lomustine (CNSP) at SNO 2025?
Who is presenting CNS Pharmaceuticals (CNSP) posters at the SNO 2025 meeting?
Where will CNS Pharmaceuticals (CNSP) poster sessions take place at SNO 2025?
How can investors find more information about CNSP presentations at SNO 2025?
